

Jaap Michiel Middeldorp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2761323/publications.pdf>

Version: 2024-02-01

183
papers

12,975
citations

19657

61
h-index

27406

106
g-index

189
all docs

189
docs citations

189
times ranked

12536
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs. <i>Clinical Chemistry</i> , 2022, 68, 953-962.	3.2	7
2	PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1553-1563.	2.8	7
3	Epstein-Barr DNA in advanced pediatric nasopharyngeal cancer. <i>Paediatrica Indonesiana</i> , 2021, 61, 261-70.	0.1	0
4	Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 757302.	4.8	27
5	Quantitative cytokine level of TNF- α , IFN- γ , IL-10, TGF- β and circulating Epstein-Barr virus DNA load in individuals with acute Malaria due to <i>P. falciparum</i> or <i>P. vivax</i> or double infection in a Malaria endemic region in Indonesia. <i>PLoS ONE</i> , 2021, 16, e0261923.	2.5	9
6	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. <i>BMC Public Health</i> , 2020, 20, 912.	2.9	90
7	Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma. <i>Clinical Oncology and Research</i> , 2020, , 1-10.	0.0	1
8	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	8
9	Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn ²⁺ -chelating function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26614-26624.	7.1	22
10	Vesicle-bound EBV-BART13 miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV infections. <i>International Journal of Cancer</i> , 2019, 144, 2555-2566.	5.1	49
11	Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus. <i>Journal of Infectious Diseases</i> , 2019, 219, 955-963.	4.0	19
12	Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome. <i>Journal of Infectious Diseases</i> , 2018, 217, 1923-1931.	4.0	13
13	Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. <i>Journal of Cell Biology</i> , 2018, 217, 1129-1142.	5.2	227
14	Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan. <i>Clinical Cancer Research</i> , 2018, 24, 1305-1314.	7.0	52
15	Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma. <i>Journal of Medical Virology</i> , 2018, 90, 191-195.	5.0	15
16	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. <i>Nature Communications</i> , 2018, 9, 4663.	12.8	106
17	Epstein-Barr Virus Gene BARP1 Expression is Regulated by the Epithelial Differentiation Factor Np63 in Undifferentiated Nasopharyngeal Carcinoma. <i>Cancers</i> , 2018, 10, 76.	3.7	14
18	Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas. <i>Cancers</i> , 2018, 10, 89.	3.7	31

#	ARTICLE	IF	CITATIONS
19	Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases. <i>Journal of Virology</i> , 2018, 92, .	3.4	75
20	Quantitative multi-target RNA profiling in Epstein-Barr virus infected tumor cells. <i>Journal of Virological Methods</i> , 2017, 241, 24-33.	2.1	12
21	Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA. <i>Journal of Virology</i> , 2017, 91, .	3.4	68
22	Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model. <i>Journal of Medical Virology</i> , 2017, 89, 2207-2216.	5.0	10
23	Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. <i>Cell Host and Microbe</i> , 2017, 22, 61-73.e7.	11.0	102
24	Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin. <i>International Journal of Cancer</i> , 2017, 140, 149-162.	5.1	48
25	Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area. <i>PLoS ONE</i> , 2017, 12, e0180683.	2.5	9
26	Epstein-Barr virus negative MS: a true phenomenon?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e318.	6.0	33
27	High Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7. <i>PLoS ONE</i> , 2017, 12, e0169290.	2.5	14
28	Human serum antibodies against EBV latent membrane protein 1 cross-react with α -synuclein. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e239.	6.0	11
29	Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. <i>International Journal of Cancer</i> , 2016, 138, 125-136.	5.1	65
30	Sensing of latent EBV infection through exosomal transfer of 5' cap RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E587-96.	7.1	136
31	Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1557-1567.	1.6	15
32	Epstein-Barr virus BART1-induced NF- κ B/miR-146a/SMAD4 alterations in stomach cancer cells. <i>Oncotarget</i> , 2016, 7, 82213-82227.	1.8	31
33	Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26334.	12.2	28
34	Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. <i>Infectious Agents and Cancer</i> , 2015, 10, 5.	2.6	2
35	A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 563-72.	4.9	28
36	Telomerase Activity Impacts on Epstein-Barr Virus Infection of AGS Cells. <i>PLoS ONE</i> , 2015, 10, e0123645.	2.5	6

#	ARTICLE	IF	CITATIONS
37	The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005344.	4.7	51
38	Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with <i>Plasmodium falciparum</i> Malaria during Pregnancy. <i>Vaccine Journal</i> , 2015, 22, 1197-1205.	3.1	27
39	Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1845-1857.	2.5	47
40	Possible contributing role of Epstein-Barr virus (EBV) as a cofactor in human papillomavirus (HPV)-associated cervical carcinogenesis. <i>Journal of Clinical Virology</i> , 2015, 73, 70-76.	3.1	21
41	Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 289-323.	1.1	49
42	Abstract 2716: Epstein-Barr virus-encoded BARF1 downregulates SMAD4 and increases miR-146a in gastric carcinoma cells. , 2015, , .		1
43	Current Status of Cancer Care for Young Patients with Nasopharyngeal Carcinoma in Jakarta, Indonesia. <i>PLoS ONE</i> , 2014, 9, e102353.	2.5	15
44	Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 721.	2.0	48
45	Seroreactivity Against Epstein-Barr Virus (Ebv) in Family Members of Ebv-Associated Nasopharyngeal Carcinoma and Non-Family Individuals. <i>Annals of Oncology</i> , 2014, 25, iv480.	1.2	0
46	Combination of SAHA and bortezomib upregulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. <i>British Journal of Haematology</i> , 2014, 167, 639-650.	2.5	25
47	Epstein-Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1213-1219.	2.5	58
48	Nontemplated Nucleotide Additions Distinguish the Small RNA Composition in Cells from Exosomes. <i>Cell Reports</i> , 2014, 8, 1649-1658.	6.4	484
49	Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 685-694.	2.2	52
50	Epstein-Barr virus viral load and serology in childhood non-Hodgkin's lymphoma and chronic inflammatory conditions in Uganda: Implications for disease risk and characteristics. <i>Journal of Medical Virology</i> , 2014, 86, 1796-1803.	5.0	16
51	Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment. <i>Clinical Cancer Research</i> , 2013, 19, 2175-2186.	7.0	60
52	BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator. <i>Reviews in Medical Virology</i> , 2013, 23, 367-383.	8.3	46
53	Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma. <i>Journal of Medical Virology</i> , 2013, 85, 524-529.	5.0	14
54	Lower mortality from nasopharyngeal cancer in The Netherlands since 1970 with differential incidence trends in histopathology. <i>Oral Oncology</i> , 2013, 49, 237-243.	1.5	34

#	ARTICLE	IF	CITATIONS
55	Virus-modified exosomes for targeted RNA delivery; A new approach in nanomedicine. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 348-356.	13.7	114
56	Analysis of Viral MicroRNA Exchange via Exosomes In Vitro and In Vivo. <i>Methods in Molecular Biology</i> , 2013, 1024, 53-68.	0.9	40
57	Epstein-Barr Virus-Encoded BARF1 Promotes Proliferation of Gastric Carcinoma Cells through Regulation of NF- κ B. <i>Journal of Virology</i> , 2013, 87, 10515-10523.	3.4	60
58	Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. <i>PLoS ONE</i> , 2013, 8, e63706.	2.5	33
59	Uji serologi IgA karakter KNF EBNA1+VCA p-18 pada penderita keluhan kronis kepala leher. <i>Oto-rhino-laryngologĳca Indonesiana</i> , 2013, 41, 105.	0.0	0
60	Contributions of the Epstein-Barr Virus EBNA1 Protein to Gastric Carcinoma. <i>Journal of Virology</i> , 2012, 86, 60-68.	3.4	78
61	Cytolytic Virus Activation Therapy for Epstein-Barr Virus-Driven Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 5061-5070.	7.0	72
62	Epstein-Barr Virus Transcription Activator R Upregulates BARF1 Expression by Direct Binding to Its Promoter, Independent of Methylation. <i>Journal of Virology</i> , 2012, 86, 11322-11332.	3.4	20
63	Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3473-82.	7.1	127
64	Epstein-Barr Virus-Encoded BARF1 Protein is a Decoy Receptor for Macrophage Colony Stimulating Factor and Interferes with Macrophage Differentiation and Activation. <i>Viral Immunology</i> , 2012, 25, 461-470.	1.3	26
65	Early Age at Time of Primary Epstein-Barr Virus Infection Results in Poorly Controlled Viral Infection in Infants From Western Kenya: Clues to the Etiology of Endemic Burkitt Lymphoma. <i>Journal of Infectious Diseases</i> , 2012, 205, 906-913.	4.0	143
66	Intracellular signaling controlled by the endosomal-exosomal pathway. <i>Communicative and Integrative Biology</i> , 2012, 5, 88-93.	1.4	29
67	Persistence of Epstein-Barr Virus in Self-Reactive Memory B Cells. <i>Journal of Virology</i> , 2012, 86, 12330-12340.	3.4	69
68	Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. <i>Chinese Journal of Cancer</i> , 2012, 31, 185-196.	4.9	220
69	Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory. <i>Clinical Epidemiology</i> , 2012, 4, 339.	3.0	23
70	Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia. <i>Journal of Medical Virology</i> , 2012, 84, 768-776.	5.0	8
71	Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 1930-1940.	5.1	73
72	EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. <i>Journal of Clinical Investigation</i> , 2012, 122, 1487-1502.	8.2	132

#	ARTICLE	IF	CITATIONS
73	Short-Term Effect of Different Teaching Methods on Nasopharyngeal Carcinoma for General Practitioners in Jakarta, Indonesia. PLoS ONE, 2012, 7, e32756.	2.5	13
74	Development of a Non-Invasive Method, Multiplex Methylation Specific PCR (MMSP), for Early Diagnosis of Nasopharyngeal Carcinoma. PLoS ONE, 2012, 7, e45908.	2.5	26
75	Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Molecular Cancer, 2011, 10, 48.	19.2	68
76	Can an online clinical data management service help in improving data collection and data quality in a developing country setting?. Trials, 2011, 12, 190.	1.6	15
77	Viral miRNAs exploiting the endosomal/exosomal pathway for intercellular cross-talk and immune evasion. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 715-721.	1.9	108
78	A human tumor virus extends its reach. Future Virology, 2011, 6, 413-415.	1.8	0
79	Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph. Haematologica, 2011, 96, 323-327.	3.5	15
80	LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF- κ B activation. EMBO Journal, 2011, 30, 2115-2129.	7.8	201
81	Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology, 2011, 410, 64-75.	2.4	79
82	Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. Journal of Medical Virology, 2011, 83, 665-678.	5.0	23
83	Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain, 2011, 134, 2772-2786.	7.6	176
84	A Novel Persistence Associated EBV miRNA Expression Profile Is Disrupted in Neoplasia. PLoS Pathogens, 2011, 7, e1002193.	4.7	123
85	Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. Journal of Virological Methods, 2010, 169, 79-86.	2.1	14
86	Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: Regulation of infection and phenotypic characterization. International Journal of Cancer, 2010, 127, 1570-1583.	5.1	80
87	Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. Journal of Medical Virology, 2010, 82, 1684-1688.	5.0	63
88	Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain, 2010, 133, e137-e137.	7.6	132
89	Exosomes. Communicative and Integrative Biology, 2010, 3, 447-450.	1.4	302
90	Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infectious Agents and Cancer, 2010, 5, 13.	2.6	40

#	ARTICLE	IF	CITATIONS
91	Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma. <i>Infectious Agents and Cancer</i> , 2010, 5, 16.	2.6	20
92	No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. <i>Journal of Clinical Virology</i> , 2010, 49, 26-31.	3.1	39
93	Functional delivery of viral miRNAs via exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6328-6333.	7.1	1,437
94	Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. <i>PLoS Pathogens</i> , 2009, 5, e1000490.	4.7	80
95	Two-Step Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent Assay System for Serological Screening and Confirmation of Nasopharyngeal Carcinoma. <i>Vaccine Journal</i> , 2009, 16, 706-711.	3.1	31
96	Epstein-Barr Virus Latency in B Cells Leads to Epigenetic Repression and CpG Methylation of the Tumour Suppressor Gene Bim. <i>PLoS Pathogens</i> , 2009, 5, e1000492.	4.7	158
97	Comprehensive Profiling of Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma. <i>Journal of Virology</i> , 2009, 83, 2357-2367.	3.4	169
98	Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. <i>Journal of Medical Virology</i> , 2009, 81, 1088-1093.	5.0	44
99	Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue. <i>Head and Neck Pathology</i> , 2009, 3, 276-282.	2.6	23
100	A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation. <i>Transplantation</i> , 2009, 88, 1025-1029.	1.0	104
101	Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. <i>Seminars in Cancer Biology</i> , 2008, 18, 388-396.	9.6	114
102	Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. <i>Journal of Clinical Virology</i> , 2008, 42, 343-352.	3.1	17
103	The DNase of Gammaherpesviruses Impairs Recognition by Virus-Specific CD8 ⁺ T Cells through an Additional Host Shutoff Function. <i>Journal of Virology</i> , 2008, 82, 2385-2393.	3.4	87
104	Reconstitution of Nasopharyngeal Carcinoma-Type EBV Infection Induces Tumorigenicity. <i>Cancer Research</i> , 2008, 68, 1030-1036.	0.9	52
105	Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. <i>Blood</i> , 2008, 111, 1739-1739.	1.4	13
106	Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3366-3371.	7.1	202
107	Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. <i>Aids</i> , 2007, 21, 2141-2149.	2.2	23
108	Epstein-Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. <i>International Journal of Cancer</i> , 2007, 121, 1806-1812.	5.1	44

#	ARTICLE	IF	CITATIONS
109	Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. <i>Journal of Medical Virology</i> , 2007, 79, 1710-1721.	5.0	33
110	Morphological Evidence of an Activated Cytotoxic T-Cell Infiltrate in EBV-Positive Gastric Carcinoma Preventing Lymph Node Metastases. <i>American Journal of Surgical Pathology</i> , 2006, 30, 59-65.	3.7	72
111	Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9. <i>BMC Cancer</i> , 2006, 6, 283.	2.6	218
112	Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy. <i>Head and Neck</i> , 2006, 28, 1040-1045.	2.0	14
113	Noninvasive diagnosis of nasopharyngeal carcinoma: Nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. <i>International Journal of Cancer</i> , 2006, 119, 608-614.	5.1	98
114	Profiling of Epstein-Barr Virus Latent RNA Expression in Clinical Specimens by Gene-Specific Multiprimed cDNA Synthesis and PCR. , 2005, 292, 027-038.		7
115	Quantitative Detection of Epstein-Barr Virus DNA in Clinical Specimens by Rapid Real-Time PCR Targeting a Highly Conserved Region of EBNA-1. , 2005, 292, 015-026.		23
116	Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 498-502.	2.0	25
117	Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. <i>Modern Pathology</i> , 2005, 18, 877-885.	5.5	24
118	Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. <i>Journal of Medical Virology</i> , 2005, 75, 593-602.	5.0	58
119	Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. <i>Journal of Medical Virology</i> , 2005, 76, 82-88.	5.0	101
120	Epstein-Barr Virus mRNA Export Factor EB2 Is Essential for Intranuclear Capsid Assembly and Production of gp350. <i>Journal of Virology</i> , 2005, 79, 14102-14111.	3.4	33
121	In Nasopharyngeal Carcinoma Cells, Epstein-Barr Virus LMP1 Interacts with Galectin 9 in Membrane Raft Elements Resistant to Simvastatin. <i>Journal of Virology</i> , 2005, 79, 13326-13337.	3.4	62
122	Human Cytomegalovirus Infection of a Severe-Burn Patient: Evidence for Productive Self-Limited Viral Replication in Blood and Lung. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2534-2536.	3.9	38
123	Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3066-3073.	3.9	86
124	EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. <i>Virology Journal</i> , 2005, 2, 39.	3.4	62
125	Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 239-244.	7.1	250
126	Molecular Diversity of Epstein-Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects. <i>Journal of Infectious Diseases</i> , 2004, 190, 53-62.	4.0	89

#	ARTICLE	IF	CITATIONS
127	Molecular Evidence for Rhesus Lymphocryptovirus Infection of Epithelial Cells in Immunosuppressed Rhesus Macaques. <i>Journal of Virology</i> , 2004, 78, 3455-3461.	3.4	31
128	Epstein-Barr Virus Infection in Ex Vivo Tonsil Epithelial Cell Cultures of Asymptomatic Carriers. <i>Journal of Virology</i> , 2004, 78, 12613-12624.	3.4	102
129	The Amino Terminus of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Contains AT Hooks That Facilitate the Replication and Partitioning of Latent EBV Genomes by Tethering Them to Cellular Chromosomes. <i>Journal of Virology</i> , 2004, 78, 11487-11505.	3.4	143
130	Cytomegalovirus (CMV) Inactivation in Breast Milk: Reassessment of Pasteurization and Freeze-Thawing. <i>Pediatric Research</i> , 2004, 56, 529-535.	2.3	188
131	EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2004, 22, 664-670.	1.6	240
132	Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. <i>Journal of Medical Virology</i> , 2003, 69, 258-266.	5.0	22
133	Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 1-36.	4.4	160
134	Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. <i>Cancer Gene Therapy</i> , 2003, 10, 121-124.	4.6	20
135	Prenatal Diagnosis of Congenital Human Cytomegalovirus Infection in Amniotic Fluid by Nucleic Acid Sequence-Based Amplification Assay. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1772-1774.	3.9	36
136	Localization of the Epstein-Barr virus protein LMP 1 to exosomes. <i>Journal of General Virology</i> , 2003, 84, 1871-1879.	2.9	146
137	In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARFO protein expression in multiple EBV-associated disorders. <i>Journal of General Virology</i> , 2003, 84, 2647-2659.	2.9	23
138	EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. <i>Blood</i> , 2003, 102, 4243-4243.	1.4	34
139	Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. <i>Blood</i> , 2003, 101, 5053-5060.	1.4	65
140	Comparison of Quantitative Competitive PCR with LightCycler-Based PCR for Measuring Epstein-Barr Virus DNA Load in Clinical Specimens. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3986-3992.	3.9	34
141	A Rapid and Reliable Enzyme Immunoassay PCR-Based Screening Method to Identify EBV-Carrying Gastric Carcinomas. <i>Modern Pathology</i> , 2002, 15, 870-877.	5.5	19
142	Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease. <i>Leukemia and Lymphoma</i> , 2002, 43, 831-840.	1.3	97
143	Molecular diagnosis of viral infections in renal transplant recipients. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 665-682.	2.0	5
144	High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. <i>Aids</i> , 2002, 16, 993-1001.	2.2	78

#	ARTICLE	IF	CITATIONS
145	Multiplex real-time NASBA for monitoring expression dynamics of human cytomegalovirus encoded IE1 and pp67 RNA. <i>Journal of Clinical Virology</i> , 2002, 24, 57-66.	3.1	29
146	Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. <i>Journal of Medical Virology</i> , 2002, 68, 370-377.	5.0	29
147	Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. <i>International Journal of Cancer</i> , 2002, 99, 93-99.	5.1	97
148	High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. <i>Journal of Pathology</i> , 2002, 198, 468-475.	4.5	63
149	TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMAB. <i>Transplantation</i> , 2002, 73, 100-104.	1.0	113
150	Epstein-Barr virus replication in tongue epithelial cells. <i>Journal of General Virology</i> , 2002, 83, 2995-2998.	2.9	41
151	Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. <i>Blood</i> , 2001, 97, 1165-1171.	1.4	309
152	Functional CD4+ and CD8+ T-Cell Responses Induced by Autologous Mitomycin C Treated Epstein-Barr Virus Transformed Lymphoblastoid Cell Lines. <i>Cellular Immunology</i> , 2001, 208, 25-33.	3.0	6
153	Direct Quantification of Human Cytomegalovirus Immediate-Early and Late mRNA Levels in Blood of Lung Transplant Recipients by Competitive Nucleic Acid Sequence-Based Amplification. <i>Journal of Clinical Microbiology</i> , 2001, 39, 251-259.	3.9	21
154	Toward Standardization of Epstein-Barr Virus DNA Load Monitoring: Unfractionated Whole Blood as Preferred Clinical Specimen. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1211-1216.	3.9	145
155	Expression Dynamics of Human Cytomegalovirus Immune Evasion Genes US3, US6, and US11 in the Blood of Lung Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2001, 184, 247-255.	4.0	18
156	Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4 + T-Helper 1 Responses. <i>Journal of Virology</i> , 2001, 75, 8649-8659.	3.4	213
157	EVALUATION OF HUMAN CYTOMEGALOVIRUS GENE EXPRESSION IN THORACIC ORGAN TRANSPLANT RECIPIENTS USING NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION. <i>Transplantation</i> , 2000, 70, 1209-1215.	1.0	17
158	Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 606-610.	5.1	21
159	Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. <i>Journal of Virological Methods</i> , 2000, 90, 193-204.	2.1	12
160	Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1. <i>Journal of Immunology</i> , 2000, 165, 663-670.	0.8	174
161	Human Cytomegalovirus Virions Differentially Incorporate Viral and Host Cell RNA during the Assembly Process. <i>Journal of Virology</i> , 2000, 74, 9078-9082.	3.4	89
162	Bioreactor-Scale Production and One-Step Purification of Epstein-Barr Nuclear Antigen 1 Expressed in Baculovirus-Infected Insect Cells. <i>Protein Expression and Purification</i> , 2000, 20, 324-333.	1.3	8

#	ARTICLE	IF	CITATIONS
163	Use of CMV transcripts for monitoring of CMV infections in transplant recipients. <i>International Journal of Antimicrobial Agents</i> , 2000, 16, 455-460.	2.5	7
164	Expression of the transforming Epstein-Barr virus BARP1 gene in EBV-carrying gastric adenocarcinomas. <i>Gastroenterology</i> , 2000, 118, A60.	1.3	7
165	Human Cytomegalovirus Immediate-Early mRNA Detection by Nucleic Acid Sequence-Based Amplification as a New Parameter for Preemptive Therapy in Bone Marrow Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1845-1853.	3.9	58
166	Diagnostic Value of Nucleic-Acid-Sequence- Based Amplification for the Detection of Cytomegalovirus Infection in Renal and Liver Transplant Recipients. <i>Intervirolgy</i> , 1999, 42, 373-381.	2.8	11
167	EARLY DETECTION OF HUMAN CYTOMEGALOVIRUS INFECTION AFTER KIDNEY TRANSPLANTATION BY NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION1. <i>Transplantation</i> , 1999, 67, 1274-1277.	1.0	35
168	Molecular Fine-Specificity Analysis of Antibody Responses to Human Cytomegalovirus and Design of Novel Synthetic-Peptide-Based Serodiagnostic Assays. <i>Journal of Clinical Microbiology</i> , 1999, 37, 179-188.	3.9	41
169	Clinical Significance of Expression of Human Cytomegalovirus pp67 Late Transcript in Heart, Lung, and Bone Marrow Transplant Recipients as Determined by Nucleic Acid Sequence-Based Amplification. <i>Journal of Clinical Microbiology</i> , 1999, 37, 902-911.	3.9	64
170	Monitoring of Epstein-Barr Virus DNA Load in Peripheral Blood by Quantitative Competitive PCR. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2852-2857.	3.9	111
171	Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin. <i>Journal of Biomedical Science</i> , 1998, 5, 173-179.	7.0	19
172	Nucleic Acid Sequence-Based Amplification, a New Method for Analysis of Spliced and Unspliced Epstein-Barr Virus Latent Transcripts, and Its Comparison with Reverse Transcriptase PCR. <i>Journal of Clinical Microbiology</i> , 1998, 36, 3164-3169.	3.9	49
173	Diagnostic Value of Monitoring Human Cytomegalovirus Late pp67 mRNA Expression in Renal-Allograft Recipients by Nucleic Acid Sequence-Based Amplification. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1341-1346.	3.9	90
174	P32/TAP, a Cellular Protein That Interacts with EBNA-1 of Epstein-Barr Virus. <i>Virology</i> , 1997, 236, 18-29.	2.4	151
175	A Major DNA Binding Protein Encoded by BALF2 Open Reading Frame of Epstein-Barr Virus (EBV) Forms a Complex with Other EBV DNA-Binding Proteins: DNAase, EA-D, and DNA Polymerase. <i>Virology</i> , 1997, 239, 285-295.	2.4	37
176	Detection of hepatitis C virus antigen by immuno-histochemical staining: a histological marker of hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 20, 275-281.	3.7	44
177	Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. <i>Journal of Medical Virology</i> , 1993, 40, 161-169.	5.0	59
178	Epstein-Barr Virus Gene Expression in Oral Hairy Leukoplakia. <i>Virology</i> , 1993, 195, 463-474.	2.4	42
179	Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells. <i>Journal of Chromatography A</i> , 1992, 599, 267-272.	3.7	17
180	Development of an antibody-capture IgM-enzyme-linked immunosorbent assay for diagnosis of acute epstein-barr virus infections. <i>Journal of Virological Methods</i> , 1988, 21, 105-115.	2.1	12

#	ARTICLE	IF	CITATIONS
181	Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. Journal of Virological Methods, 1988, 21, 133-146.	2.1	68
182	Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. Journal of Virological Methods, 1988, 21, 147-159.	2.1	55
183	A Stimulatory Role for Cytomegalovirus (CMV) Antibodies in CMV-Specific Lymphocyte Proliferation in vitro. Intervirology, 1983, 20, 114-122.	2.8	5